Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new discovery from the Lakhal-Littleton Group on how iron deficiency affects the vasculature of the lung could hold the key to improving treatment of pulmonary arterial hypertension.

This new paper from the Lakhal-Littleton Group describes the way in which iron deficiency affects our vasculature, in particular the vasculature of the lung.

Iron deficiency is the most common nutritional disorder in the word.  Its prevalence is particularly high in patients with cardiovascular diseases, in whom it is associated with poor outcome.

It has been known for some time that iron deficiency predisposes to pulmonary arterial hypertension (PAH). In this condition, the vasculature in the lungs is constricted and remodelled, and this puts pressure on the right side of the heart. For some time it was thought that PAH is caused by anaemia, a condition in which iron deficiency is the underlying mechanism. Consequently, the only consideration given to iron deficiency in the clinical setting has been in the context of correcting anaemia.

However, previous work from this laboratory has shown that iron deficiency within tissues, such as the heart, is sufficient to cause disease even in the absence of anaemia. Through eLife publication, “An essential cell-autonomous role for hepcidin in cardiac iron homeostasis”, Prof Lakhal-Littleton and her team revealed the first study describing the mechanism linking iron deficiency with heart disease. 

This new study explores the links between iron deficiency and PAH. It has found that iron deficiency within the smooth muscle cells of the pulmonary arteries is in itself sufficient to cause PAH, even in the absence of anaemia. The effect of iron deficiency is due to increased release of the vasoconstrictor endothelin-1 from cells of the pulmonary arteries.

Prof Lakhal-Littleton and her team were able to reverse and prevent PAH in mice by both iron supplementation and inhibition of endothelin-1 signalling. Consequently, this study provides a mechanistic underpinning for the observation that iron deficiency raises hypoxic pulmonary arterial pressure in healthy individuals and worsens existing PAH in patients. 

Ultimately, this paper demonstrates that it is not anaemia, but rather the lack of iron in the cells of the vasculature that is causing the remodelling of the vessels in the lung present in individuals suffering from PAH. Therefore, it strengthens the rationale for correction of tissue iron deficiency independently of the presence or absence of anaemia.

 

It holds potential to alter the way in which patients with pulmonary arterial hypertension are treated. Now that this study is published, it provides the rationale for giving iron to patients even when they aren't anaemic, because the target is no longer anaemia, but iron deficiency within tissues. - Associate Professor Samira Lakhal-Littleton

Read the full paper Intracellular iron deficiency in pulmonary arterial smooth muscle cells causes pulmonary arterial hypertension in mice published in PNAS, here.

The full interview with Associate Professor Samira Lakhal-Littleton is available with subtitles here, where she also discusses the implications of this study on future research avenues.

More information is also available on the University of Oxford website.

SLL lab- summary slide.png

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

Winners of the DPAG Student Poster Day 2022 announced

"A Year of Progress" was held in the Sherrington Library on Wednesday 9 November 2022.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.